This study is looking at a treatment approach for people with blood cancers (hematologic malignancy) that need a stem cell transplant. It's testing the safety and effectiveness of a specific transplant method called RIC HIDT, which uses a reduced dose of fludarabine and intermediate-dose total body irradiation (TBI) before a haplo-identical (partially matched) stem cell transplant. You might be able to join if you are 18 or older, have a good performance status (KPS ≥ 70%), and have a partially matched family donor. The study will measure how quickly your white blood cells (neutrophils) and platelets recover after the transplant, and look for signs of graft rejection within 30 days. The current status of this study is unclear.

Study design

This is an observational study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure outcomes for at least 30 days after transplant to determine the incidence of graft rejection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.